The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis.
Open accessPublished version of a preprint
Abstract
Cell-cycle inhibition has yet to offer a generally effective approach to cancer treatment, but a full evaluation of different combinations of cell-cycle inhibitors has not been evaluated. Cyclin A2, a core component of the cell cycle, is often aberrantly expressed in cancer where it may impact cell proliferation. In this study, we investigated the role of cyclin A2 in tumorigenesis using a conditional genetic knockout mouse model. Cyclin A2 deletion in oncogene-transformed mouse embryonic fibroblasts (MEF) suppressed tumor formation in immunocompromised mice. These findings were confirmed in mice with cyclin A2-deficient hepatocytes, where a delay in liver tumor formation was observed. Because cyclin A2 acts in complex with Cdk2 in the cell cycle, we explored a hypothesized role for Cdk2 dysregulation in this effect through conditional deletions of both genes. In oncogene-transformed MEFs lacking both genes, tumor formation was strongly suppressed in a manner associated with decreased proliferation, premature senescence, and error-prone recovery from serum deprivation after immortalization. Whereas loss of cyclin A2 led to a compensatory increase in Cdk1 activity, this did not occur with loss of both Cdk2 and cyclin A2. Our work offers a rationale to explore combinations of Cdk1 and Cdk2 inhibitors as a general approach in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As cyclin A2 deregulation is associated with aberrant cell proliferation (Gopinathan et al., 2014), these findings suggest another way in which USP7 upregulation may promote oncogenesis.”
From USP7 Is a Master Regulator of Genome Stability (2020) · cites this paper as Gopinathan et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“Aberrant expression of cyclin A2 has been detected in a variety of cancers, and deregulation of cyclin A2 appears to be closely related to chromosomal instability and tumor proliferation (3, 12, 13).”
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Cyclin A is required at two points in the human cell cycle.
Pagano, M., Pepperkok, R., Verde, F., Ansorge, W. J., & Draetta, G. F. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05135.x · Cited by 1,403
Lee, E.-C., Yu, D., de Velasco, J. M., Tessarollo, L., Swing, D. A., Court, D. L., Jenkins, N. A., & Copeland, N. G. (2001) · Genomics · doi:10.1006/geno.2000.6451 · Cited by 1,180
High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP
Rodríguez, C. I., Buchholz, F., Galloway, J. L., Sequerra, R., Kasper, J. S., Ayala, R., Stewart, A. F., & Dymecki, S. M. (2000) · Nature Genetics · doi:10.1038/75973 · Cited by 1,162
Cyclin a is required for the onset of DNA replication in mammalian fibroblasts
Girard, F., Strausfeld, U. P., Fernandez, A., & Lamb, N. J. C. (1991) · Cell · doi:10.1016/0092-8674(91)90293-8 · Cited by 880
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Priéto, I., Odajima, J., Martín, A. L., Dubus, P. R., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 798
Berthet, C., Aleem, E. A., Coppola, V., Tessarollo, L., & Kaldis, P. (2003) · Current Biology · doi:10.1016/j.cub.2003.09.024 · Cited by 665
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Swenson, K. I., Farrell, K. M., & RUDERMAN, J. V. (1986) · Cell · doi:10.1016/0092-8674(86)90801-9 · Cited by 535
Cyclin A in cell cycle control and cancer
Yam, C. H., Fung, T. K., & Poon, R. Y. C. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8510-y · Cited by 519
Geley, S., Kramer, E., Gieffers, C., Gannon, J., Peters, J., & Hunt, T. (2001) · Journal of Cell Biology · doi:10.1083/jcb.153.1.137 · Cited by 462
Diril, M. K., Ratnacaram, C. K., Padmakumar, V. C., Du, T., Wasser, M., Coppola, V., Tessarollo, L., & Kaldis, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115201109 · Cited by 385
Cdc2–cyclin E complexes regulate the G1/S phase transition
Aleem, E. A., Kiyokawa, H., & Kaldis, P. (2005) · Nature Cell Biology · doi:10.1038/ncb1284 · Cited by 383
Cyclin a Is Destroyed in Prometaphase and Can Delay Chromosome Alignment and Anaphase
den Elzen, N. R., & Pines, J. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.1.121 · Cited by 372
Analysis of Fgf8 gene function in vertebrate development.Preprint
Lewandoski, M. B., Meyers, E. N., & Martin, G. R. (1997) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1997.062.01.021 · Cited by 300
Delayed early embryonic lethality following disruption of the murine cyclin A2 gene
Murphy, M., Stinnakre, M., Sénamaud‐Beaufort, C., Winston, N. J., Sweeney, C., Kubelka, M., Carrington, M., Bréchot, C., & Sobczak‐Thépot, J. (1997) · Nature Genetics · doi:10.1038/ng0197-83 · Cited by 279
Cyclin A is required in S phase in normal epithelial cells
Zindy, F., Lamas, E., Chenivesse, X., Sobczak‐Thépot, J., Wang, J., Fesquet, D., Henglein, B., & Bréchot, C. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91851-g · Cited by 271
Human Cyclin a Is Required for Mitosis until Mid Prophase
Furuno, N., den Elzen, N. R., & Pines, J. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.2.295 · Cited by 254
Cyclin A Is Redundant in Fibroblasts but Essential in Hematopoietic and Embryonic Stem Cells
Kalaszczynska, I., Geng, Y., Iino, T., Mizuno, S.-I., Choi, Y., Kondratiuk, I., Silver, D. P., Wolgemuth, D. J., Akashi, K., & Sicinski, P. (2009) · Cell · doi:10.1016/j.cell.2009.04.062 · Cited by 215
Bukholm, I., Bukholm, G., & Nesland, J. M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1311 · Cited by 206
p21 Inhibits Cdk1 in the Absence of Cdk2 to Maintain the G1/S Phase DNA Damage Checkpoint
Ande, S., Hilton, M. B., & Kaldis, P. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-06-0525 · Cited by 168
Combined Loss of Cdk2 and Cdk4 Results in Embryonic Lethality and Rb Hypophosphorylation
Berthet, C., Klarmann, K. D., Hilton, M. B., Suh, H. C., Keller, J. R., Kiyokawa, H., & Kaldis, P. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.03.004 · Cited by 152
Carlson, C. M., Frandsen, J. L., Kirchhof, N., McIvor, R. S., & Largaespada, D. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502974102 · Cited by 134
Chao, Y., Shih, Y., Chiu, J., Chau, G. Y., Lui, W., Yang, W. K., Lee, S., & Huang, T. (1998) · PubMed · Cited by 110
Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas
Volm, M., Koomägi, R., Mattern, J., & Stammler, G. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.302 · Cited by 100
E- and A-type cyclins as markers for cancer diagnosis and prognosis
Yasmeen, A., Berdel, W. E., Serve, H. L., & Müller‐Tidow, C. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.5.617 · Cited by 83
A Detailed Analysis of Cyclin A Accumulation at the G1/S Border in Normal and Transformed Cells
Erlandsson, F., Linnman, C., Ekholm, S. V., Bengtsson, E. W., & Zetterberg, A. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4889 · Cited by 76
Chen, W., Lee, J., Cho, S. Y., & Fine, H. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3906 · Cited by 65
A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver
Wangensteen, K. J., Wilber, A. C., Keng, V. W., He, Z., Matise, I., Wangensteen, L., Carson, C. M., Chen, Y., Steer, C. J., McIvor, S. R., et al. (2008) · Hepatology · doi:10.1002/hep.22195 · Cited by 59
Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer
Poikonen‐Saksela, P., Sjöström, J., Amini, R.-M., Villman, K., Ahlgren, J., & BLOMQVIST, C. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602735 · Cited by 55
How to become immortal: let MEFs count the ways
Odell, A. F., Askham, J. M., Whibley, C., & Hollstein, M. (2010) · Aging · doi:10.18632/aging.100129 · Cited by 44
Wołowiec, D., Berger, F., Ffrench, P., Bryon, P. A., & Ffrench, M. (1999) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199909145714 · Cited by 34
Ubiquitous postnatal LoxP recombination using a doxycycline auto-inducible Cre transgene (DAI-Cre)
Holzenberger, M., Zaoui, R., Leneuve, P., Hamard, G., & Bouc, Y. L. (2000) · genesis · doi:10.1002/(sici)1526-968x(200002)26:2 · Cited by 23
Cited by
Sorted by citations
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,931
Pyroptosis: A new frontier in cancer
Fang, Y., Tian, S., Pan, Y., Li, W., Wang, Q., Tang, Y. R., Yu, T., Wu, X., Shi, Y., Ma, P., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109595 · Cited by 1,073
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Siciński, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 587
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
Zhang, H., Deng, T., Ge, S., Liu, Y., Bai, M., Zhu, K., Fan, Q., Li, J., Ning, T., Tian, F., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0619-z · Cited by 303
Retracted
Metadata
- Authors
- Gopinathan, L., Tan, S. L. W., Padmakumar, V. C., Coppola, V., Tessarollo, L., & Kaldis, P.
- Affiliations
- Agency for Science, Technology and Research (SG)
- National Cancer Institute (US)
- Corresponding author
- Kaldis, Philipp
- Venue
- Cancer Research
- Published
- 2014-07-14
- Volume
- 74
- Issue
- 14
- Pages
- 3870-3879
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC4102624
- OpenAlex
- W2166466732
- Cited by
- 123
- References
- 36
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 11 · 2023: 6 · 2022: 15 · 2021: 22 · 2020: 14 · 2019: 16 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 8 · 2014: 2
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- American Association for Cancer Research
- National Institutes of Health
- Institute of Molecular and Cell Biology
- Biomedical Research Council
- National Cancer Institute (Z01SC010367)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin A2, CDK2, CDK1, cell cycle, carcinogenesis, cell proliferation, premature senescence, hepatocellular carcinoma, cell cycle inhibitors, conditional knockout mice
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Disease Models, Animal, Enzyme Activation, Fibroblasts, Liver Neoplasms, CDC2 Protein Kinase, Cellular Senescence, Gene Deletion, Tumor Burden, Cell Proliferation, Cyclin-Dependent Kinase 2, Mice, Gene Knockdown Techniques, Cyclin A2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
